{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"111","value":"281"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"}],"units":"Participants"}],"title":"Cycle 1 Day 1/30 Min Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.4","value":"102"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"}],"units":"Participants"}],"title":"Cycle 2 Day 1/Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.9","value":"149"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"}],"units":"Participants"}],"title":"Cycle 3 Day 1/Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"75.5","value":"181"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"}],"units":"Participants"}],"title":"Cycle 4 Day 1/Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"158","value":"431"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"}],"units":"Participants"}],"title":"Cycle 4 Day 1/30 Min Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"97.7","value":"122"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"}],"units":"Participants"}],"title":"Study Drugs Discontinuation Visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"223"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received vemurafenib, 960 mg (four, 240 mg tablets) PO, BID along with cobimetinib 60 mg (three, 20 mg tablets) PO, QD on Days 1 to 21 only followed by vemurafenib 720 mg (three, 240 mg tablets) PO, BID and vemurafenib matching placebo, PO, BID on Days 22 to 28 during the 28 day run-in period. During triple combination period (Cycle 1 onwards), participants received atezolizumab 840 mg as IV infusion on Days 1 and 15, cobimetinib, 60 mg (three, 20 mg tablets) PO, QD, on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28. Study treatment was continued until investigator determined PD, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurred first.","id":"OG000","title":"Arm B: Atezo + Cobi + Vem"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK)-evaluable population included all participants who have received any dose of atezolizumab and for whom at least one evaluable PK sample was collected. Number analyzed is the number of participants with data available for analysis at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Pre-infusion Day 1 of Cycles 1-4; 30 minutes post-infusion Day 1 of Cycles 1 and 4; at Atezolizumab discontinuation (up to approximately 33 months) (1 Cycle = 28 days)","title":"Serum Concentration of Atezolizumab","type":"SECONDARY","unitOfMeasure":"micrograms per milliliters (ug/mL)"}